Amicus Therapeutics to Present at Upcoming Investor Conferences in September.
ByAinvest
Friday, Aug 29, 2025 7:03 am ET1min read
FOLD--
Amicus Therapeutics, headquartered in Princeton, New Jersey, is committed to developing first- and best-in-class medicines for rare diseases. The company's pipeline includes cutting-edge therapies designed to address unmet medical needs. The upcoming presentations will provide investors with insights into the company's progress and future plans [2].
The Cantor Global Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference are renowned events that attract prominent industry leaders, analysts, and investors. Amicus Therapeutics' participation in these conferences underscores its commitment to transparency and engagement with the investment community.
For more information about Amicus Therapeutics and its upcoming presentations, investors can visit the company's investor relations section at https://ir.amicusrx.com/events-and-presentations [1].
References:
[1] https://www.stocktitan.net/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-oh4kt9fwyrg0.html
[2] https://www.marketscreener.com/news/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-september-2025-ce7c50ddd98ffe21
Amicus Therapeutics, a biotechnology company focused on rare diseases, will present at the Cantor Global Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference in September 2025. The company's management team will participate in the presentations, which can be accessed via the Amicus Therapeutics corporate website. Amicus Therapeutics is committed to advancing and expanding its pipeline of high-quality medicines for rare diseases.
Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company dedicated to rare diseases, has announced its participation in two major healthcare investor conferences in September 2025. The company will present at the Cantor Global Healthcare Conference on September 3 at 10:20 a.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 3:20 p.m. ET. Both presentations will be accessible via live audio webcast through the investor relations section of Amicus Therapeutics' corporate website [1].Amicus Therapeutics, headquartered in Princeton, New Jersey, is committed to developing first- and best-in-class medicines for rare diseases. The company's pipeline includes cutting-edge therapies designed to address unmet medical needs. The upcoming presentations will provide investors with insights into the company's progress and future plans [2].
The Cantor Global Healthcare Conference and Morgan Stanley 23rd Annual Global Healthcare Conference are renowned events that attract prominent industry leaders, analysts, and investors. Amicus Therapeutics' participation in these conferences underscores its commitment to transparency and engagement with the investment community.
For more information about Amicus Therapeutics and its upcoming presentations, investors can visit the company's investor relations section at https://ir.amicusrx.com/events-and-presentations [1].
References:
[1] https://www.stocktitan.net/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-oh4kt9fwyrg0.html
[2] https://www.marketscreener.com/news/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-september-2025-ce7c50ddd98ffe21
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet